Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct 1;179(10):1424-1425.
doi: 10.1001/jamainternmed.2019.0999.

Association of Biologic Prescribing for Inflammatory Bowel Disease With Industry Payments to Physicians

Affiliations

Association of Biologic Prescribing for Inflammatory Bowel Disease With Industry Payments to Physicians

Rishad Khan et al. JAMA Intern Med. .

Abstract

This economic evaluation examines whether pharmaceutical industry payments to gastroenterologists are associated with how often they prescribe the pharmaceuticals’ drugs for inflammatory bowel disease.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Khan reported research grants from AbbVie and Ferring Pharmaceuticals and research funding from Pendopharm. Dr Grover reported research grants and personal fees from AbbVie and Ferring Pharmaceuticals, personal fees from Takeda, grants from Janssen, and equity in Volo Healthcare. No other disclosures were reported.

Figures

Figure.
Figure.. Associations of Industry Payments With Prescriptions for Biologic Medications
Total payments received by each physician are plotted on the horizontal axis, while total cost associated with prescriptions written by each physician is plotted on the vertical axis. A, Association of industry payments with prescription numbers for 3737 physicians prescribing adalimumab. B, Association of industry payments with prescription numbers for 621 physicians prescribing certolizumab.

Comment in

  • doi: 10.1001/jamainternmed.2019.1081

Similar articles

Cited by

References

    1. Yu H, MacIsaac D, Wong JJ, et al. . Market share and costs of biologic therapies for inflammatory bowel disease in the USA. Aliment Pharmacol Ther. 2018;47(3):364-370. doi:10.1111/apt.14430 - DOI - PMC - PubMed
    1. Khan R, Scaffidi MA, Rumman A, Grindal AW, Plener IS, Grover SC. Prevalence of financial conflicts of interest among authors of clinical guidelines related to high-revenue medications. JAMA Intern Med. 2018;178(12):1712-1715. doi:10.1001/jamainternmed.2018.5106 - DOI - PMC - PubMed
    1. Marshall DC, Jackson ME, Hattangadi-Gluth JA. Disclosure of industry payments to physicians: an epidemiologic analysis of early data from the Open Payments program. Mayo Clin Proc. 2016;91(1):84-96. doi:10.1016/j.mayocp.2015.10.016 - DOI - PMC - PubMed
    1. Medicare Provider Utilization and Payment Data Part D Prescriber. Baltimore, MD: Centers for Medicare & Medicaid Services; 2015. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Tren.... Accessed July 18, 2018.
    1. Open Payments Baltimore, MD: Centers for Medicare & Medicaid Services; 2015. https://www.cms.gov/openpayments/. Accessed July 18, 2018.